11.06.26 -- Accelerating Biologics From Discovery To Commercial Scale

Produce recombinant proteins at scale with stable expression, flexible batch sizes, and streamlined manufacturing.

Streamline early biologics development by combining model-guided sequence selection with parallel scale-up strategies to overcome cell line unpredictability and reduce tech transfer risks.

By combining robust development expertise with scalable GMP manufacturing and comprehensive analytical support, we provide a seamless pathway from process characterization and clinical supply production to long-term commercial success.

Advanced nanotechnology improves biologics with higher drug loads, better stability, new delivery routes, and enhanced performance in injectables, inhalation, and long‑acting therapies.

Accelerate biologics development with scalable recombinant protein production across mammalian, microbial, insect, and yeast systems, from expression and purification through characterization and GMP readiness.

Precision purification strategies can simplify microbial downstream processing. Learn how streamlined workflows help shorten development timelines while supporting protein production.

Pharma and biotech developers rely on adaptable fill‑finish capacity to meet evolving market demands, scale products from clinical to commercial, and respond rapidly to public‑health emergencies.

A science‑driven CRDO model accelerates biologic development by combining expert formulation, analytics, and partnerships to reduce risk and improve outcomes.

Transitioning to rapid molecular detection via digital PCR reduces the timeline to four days, ensuring patient safety and accelerating the delivery of life-saving therapies.

To meet mAb, bispecific, and multispecific expression needs, sponsors require a proven cell line platform that delivers high‑titer, stable expression for complex proteins.

Explore end-to-end services offered by a trusted CDMO partner with more than 15 years of industry-leading experience in conjugation and purpose-built manufacturing facilities.

Corvus, a small biotech developing precision medicines, primarily for oncology patients, was seeking to develop a monoclonal antibody called CPI06, now known as Mupadolimab.